All In Biotech

Drug Trial Radar · NCT01404312

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Last checked: Nov 19, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,000

Actual

Start

May 23, 2012

Primary completion

Nov 14, 2017

Study completion Nov 14, 2017

Sponsor

Sponsor type
NIH
First posted
Jul 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety and effectiveness of a 4-week regimen of rifapentine (RPT) plus INH versus a standard 9-month regimen of INH in HIV-infected people who are at risk of developing active TB.

Conditions

  • Tuberculosis
  • HIV Infections

Interventions

  • Rifapentine (RPT)Drug

    RPT dosing was be based on participants' weight: Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets). Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets). Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets).

  • Isoniazid (INH)Drug

    Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.

  • Pyridoxine (Vitamin B6)Dietary supplement

    Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines. Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH. Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown CauseTime frame: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)

Locations

45 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program

    La Jolla, California

  • University of Southern California CRS

    Los Angeles, California

  • UCSD Antiviral Research Center CRS

    San Diego, California

  • Ucsf Hiv/Aids Crs

    San Francisco, California

  • Harbor-UCLA CRS

    Torrance, California

  • University of Colorado Hospital CRS

    Aurora, Colorado

  • Denver Public Health CRS

    Denver, Colorado

  • The University of Miami AIDS Clinical Research Unit (ACRU) CRS

    Miami, Florida

  • Northwestern University CRS

    Chicago, Illinois

  • Boston Medical Center CRS

    Boston, Massachusetts

  • Henry Ford Hosp. CRS

    Detroit, Michigan

  • Cooper Univ. Hosp. CRS

    Camden, New Jersey

  • New Jersey Medical School Clinical Research Center CRS

    Newark, New Jersey

  • Nyu Ny Nichd Crs

    New York, New York

  • Columbia P&S CRS

    New York, New York

  • Bronx-Lebanon Hospital Center NICHD CRS

    The Bronx, New York

  • Chapel Hill CRS

    Chapel Hill, North Carolina

  • Duke University Medical Center CRS

    Durham, North Carolina

  • Trinity Health and Wellness Center CRS

    Dallas, Texas

  • Houston AIDS Research Team CRS

    Houston, Texas

  • University of Washington AIDS CRS

    Seattle, Washington

  • Gaborone CRS

    Gaborone, Botswana

  • Molepolole CRS

    Gaborone, Botswana

  • Hospital Federal dos Servidores do Estado NICHD CRS

    Rio de Janeiro, Brazil

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

    Rio de Janeiro, Brazil

  • Hosp. Geral De Nova Igaucu Brazil NICHD CRS

    Rio de Janeiro, Brazil

  • Inst de Infectologia Emilio Ribas Sao Paulo Brazil NICHD CRS

    São Paulo, Brazil

  • Hospital Nossa Senhora da Conceicao CRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Univ. of Sao Paulo Brazil NICHD CRS

    São Paulo, São Paulo, Brazil

  • Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS

    Port-au-Prince, Haiti

  • GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS

    Port-au-Prince, Haiti

  • Moi University Clinical Research Center (MUCRC) CRS

    Eldoret, Kenya

  • Kisumu Crs

    Kisumu, Nyanza, Kenya

  • Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS

    Kericho, Rift Valley, Kenya

  • Blantyre CRS

    Blantyre, Malawi

  • Malawi CRS

    Lilongwe, Central Region, Malawi

  • Barranco CRS

    Lima, Peru

  • San Miguel CRS

    Lima, Peru

  • Soweto ACTG CRS

    Johannesburg, Gauteng, South Africa

  • Wits Helen Joseph Hospital CRS (Wits HJH CRS)

    Johannesburg, Gauteng, South Africa

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.